At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 1,232 enrolled
Drug / intervention
vismodegibdrug
Likely dose
vismodegib 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Arm, Open-label, Phase II, Multicentre Study, to Assess the Safety of Vismodegib (GDC-0449) in Patient With Locally Advanced or Metastatic Basal Cell Carcinoma (BCC)
In Brief
A Phase 2 clinical trial evaluating vismodegib for Basal Cell Carcinoma. Completed, enrolled 1,232 participants across 181 sites in 37 countries.
Detailed Summary
This single-arm, open-label, multi-center study will evaluate the safety and efficacy of vismodegib (GDC-0449) in patients with locally advanced or metastatic basal cell carcinoma. Patients will receive oral doses of vismodegib 150 mg once daily until disease progression or unacceptable toxicity.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBasal Cell Carcinoma
CountriesArgentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Colombia, Croatia, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Lithuania, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey (Türkiye), United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJun 2011
Enrollment StartJul 2011
Primary CompletionJun 2017
TodayJul 2026
First PostedJun 7, 2011
Enrollment StartJul 1, 2011
Primary CompletionJun 14, 2017
TodayJul 2, 2026
Enrollment to primary: 6.0 yearsPosted 15.1 years ago
Interventions
vismodegibdrug
150 mg once daily until disease progression or unacceptable toxicity